A trial of AZD1208 for solid tumours and lymphoma

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

All cancer types




Phase 1

A trial looking at AZD1208 for solid tumours Open a glossary item and lymphomas Open a glossary item that have continued to grow despite having other treatment, or for which there is no standard treatment Open a glossary item available. In this trial, a solid tumour is any cancer other than leukaemia Open a glossary item.

Doctors use treatments such as surgery, radiotherapy, chemotherapy, hormone therapy and biological therapy to treat cancer. But sometimes cancers continue to grow despite having all the standard treatments. Researchers are looking for new treatments to help people in this situation. In this trial, they are looking at a new drug called AZD1208.

AZD1208 is a type of biological therapy.  It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.

The main aims of this study are to

  • Find the highest dose of AZD1208 you can safely have
  • Learn more about the side effects and what happens to AZD1208 in your body
  • See how the drug affects lymphomas and solid tumours

Who can enter

You may be able to enter this trial if you

  • Have lymphoma Open a glossary item or a solid tumour Open a glossary item that has got worse despite having other treatments, or there is no other standard treatment Open a glossary item available
  • Have cancer or lymphoma that your doctors can see and measure on a scan
  • Are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
  • Have satisfactory blood test results
  • Are at least 18 years old
  • Are willing to use reliable contraception during the trial and for 4 weeks afterwards if you are a woman who could possibly become pregnant – male patients must use  a condom during the trial and for up to 3 months afterwards if there is any chance their partner could become pregnant

You cannot enter this trial if you

  • Have cancer that has spread to your spine (spinal cord compression) or brain, unless this has been successfully treated, is not getting any worse or causing symptoms and you haven’t needed to take steroids for at least 4 weeks
  • Have had an experimental drug as part of another clinical trial in the last 4 weeks
  • Have already had AZD1208
  • Have had any other cancer drugs in the last 3 weeks (6 weeks if you had a mitomycin C or a drug called a nitrosourea Open a glossary item)
  • Have had major surgery in the last 4 weeks
  • Have had radiotherapy to treat a large area of your body in the last 4 weeks, or radiotherapy to a small area to control symptoms in the last 2 weeks
  • Have not recovered from side effects of earlier treatment (apart from hair loss) unless they are very mild
  • Have had a heart attack in the last 3 months, or have certain other heart problems – the trial team can advise you about this
  • Have problems with your digestive system Open a glossary item that could affect you swallowing or absorbing capsules
  • Have hepatitis B, hepatitis C or HIV
  • Have any other medical condition that can’t be controlled with medication
  • Are known to be allergic to anything in AZD1208 or to similar drugs
  • Are pregnant or breastfeeding

Trial design

This phase 1 trial will recruit about 50 people. There are 2 parts to the trial – part A and part B. In part A, the researchers are trying to work out the best dose of AZD1208 to give.

Everybody taking part will have AZD1208. The first few patients have a low dose. If they don’t have any serious side effects, the next few patients have a higher dose. And so on, until the researchers find the highest dose that can be given safely. This is called a dose escalation study.

In part B, the researchers want to learn more about what happens to AZD1208 in your body, the side effects and how it affects your cancer or lymphoma. Everybody joining this part of the trial has the highest safe dose of AZD1208 that was found in part A.

You take AZD1208 capsules by mouth. You have a single dose of the drug and then between 3 and 7 days later you start taking it every day.

As long as you don’t have bad side effects, you can carry on having AZD1208 for as long as it is helping you.

Hospital visits

You see the trial team and have some tests before you start treatment. The tests include

  • Physical examination
  • Blood tests
  • Heart traces (ECGs Open a glossary item)
  • Chest X-ray (if needed)

If you have a solid tumour, you also have a CT scan or MRI scan. If you have lymphoma, you may have a PET scan.

You must agree to the researchers getting a sample of your cancer or lymphoma that was removed when you had surgery or a biopsy Open a glossary item in the past.

You go to hospital to have your first dose of AZD1208 and then on each of the following 2 days.

A few days later, you start taking the drug each day. You go to hospital 5 times in the first 3 weeks and then once a week after that. If you carry on taking AZD1208 for longer than 36 weeks, your hospital visits then reduce to once every 3 weeks. The trial team will give you more information about any tests and scans you need to have at each visit.

On some days in the first few weeks of treatment, the trial team will take a number of extra blood and urine samples both before and after you take AZD1208.These samples will help them to see how your body absorbs the drug and how it gets rid of it. This is called pharmacokinetics Open a glossary item.

The researchers will ask you to have a biopsy Open a glossary item before and after your first dose of AZD1208. They will study the tissue samples to learn more about the effect AZD1208 has on your cancer or lymphoma. This is called pharmacodynamics Open a glossary item.

They will also ask you to have more biopsies and blood tests during the trial to look for substances called biomarkers Open a glossary item. A biomarker is something that can be measured to show if the treatment is working.

You don’t have to have these extra blood tests and biopsies for pharmacodynamics or biomarker research if you don’t want to. You can still take part in the trial.

When you finish treatment, you see the trial team again and have a physical examination, blood tests, ECGs and a CT, MRI or PET scan. If you have lymphoma, you may also have a bone marrow test.

A member of the trial team will phone you 4 weeks later to see how you are.

Side effects

This is the first time that AZD1208 is being tested in people with solid tumours or lymphomas, so there may be some side effects we don’t know about yet. Possible side effects include

In men, AZD1208 may cause changes to the testicles that could lead to infertility Open a glossary item.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Johann de Bono
Professor Malcolm Ranson

Supported by

Experimental Cancer Medicine Centre (ECMC)

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 10681

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page